Cross-Sector entity
Of the tracked stories, 2 of 4 also mention Chinese biotech industry, the most common co-covered peer. The 92-day window averages about 0.3 stories each week. The busiest single day carried 2. The clearest coverage concentration is clinical-trial: 2 of 4 stories, with the rest divided among 2 other categories.
4 verified stories tracked
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 4 also mention Chinese biotech industry, the most common co-covered peer. The 92-day window averages about 0.3 stories each week. The busiest single day carried 2. The clearest coverage concentration is clinical-trial: 2 of 4 stories, with the rest divided among 2 other categories. We currently track 4 Cross-Sector stories that mention National Medical Products Administration, published between March 25, 2026 and June 24, 2026. The tracked stories average 6 original sources each.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering National Medical Products Administration. Shared-story counts are live from our verified record — not editorial picks.
NMPA releases 2025 report
China's National Medical Products Administration publishes comprehensive statistics on the record-breaking clinical trial activity.
Phase III Initiation
First patient dosed at Peking Union Medical College Hospital in China.
Cost advantages quantified
At the Outsourcing in Clinical Trials conference in California, China's trial costs were reported 50–60% lower and timelines faster than in the US.
Regulatory Designations
FDA grants Fast Track and NMPA grants Breakthrough Therapy status.
Regulatory Designations
HMI-115 receives FDA Fast Track and NMPA Breakthrough Therapy designations.
Trial Expansion
Continued enrollment across global multicenter sites for the 24-week study.
Phase II Data Publication
Results showing efficacy without hormonal side effects published in The Lancet.
Record trial count achieved
5,215 clinical drug trials registered, more than double 2020, with 57.5% being new drug trials and cancer treatments dominating.
Pre-surge baseline
Approximately 2,600 clinical drug trials registered in China (implied by 2025 doubling).
China’s clinical drug trials hit a record 5,215 in 2025, with costs 50–60% lower than in the US. This surge, driven by Beijing’s biotech ambitions, is reshaping global drug development and raising national security concerns in Washington as Chinese firms gain dominance in cancer and vaccine research.
With 5,215 clinical drug trials registered in 2025, China has more than doubled its pipeline since 2020, with 57.5% focused on novel drugs and cancer treatments topping the list. The rapid expansion and 50–60% cost advantage compared to the US are reshaping the global biopharma landscape, but Washington is scrutinizing implications for drug quality and security.
Source: Julie Zhang (hk) · Julie Zhang (hk)
Hope Medicine Inc. has initiated dosing in its Phase III clinical trial for HMI-115, a first-in-class non-hormonal monoclonal antibody for endometriosis. This milestone marks the first time a non-hormonal treatment for this condition has reached Phase III development globally, offering a potential alternative to traditional hormonal therapies.
Hope Medicine Inc. has initiated Phase III dosing for HMI-115, the first non-hormonal monoclonal antibody for endometriosis to reach this clinical stage. This milestone, supported by FDA Fast Track and NMPA Breakthrough designations, signals a potential shift away from traditional hormone-suppressing therapies in women's health.
Source: Woonsocketcall · Laotian Times
